Halo Elite

The question

Does adding Halo Elite improve my lifting performance enough to matter when load, effort and the surrounding routine stay comparable? The primary readout is repetitions completed across two fixed-load working sets. Recovery, bodyweight and tape measurements provide supporting context.

Product and planned amount

The product is Blackstone Labs Halo Elite. Its label lists 900 mg of Eucommia ulmoides 100:1 bark extract per three-tablet serving. My planned intervention is one serving daily, without escalation during the main comparison. I will confirm that my bottle matches the documented label before first use.

At three tablets a day, 27 days requires 81 tablets from a 90-tablet bottle. The duration fits three complete training rotations and the supply already on hand. It is a personal pilot length, not a clinically established treatment duration.

Daily timing

On lifting days, the planned serving is 30 to 60 minutes before training. On cardio-only and off days, it is after lunch, with a consistent relationship to food. Use remains daily across all 27 intervention days. This follows the manufacturer's training and nontraining-day directions, with cardio-only days assigned to the nonlifting schedule for this experiment.

Each administration is logged. A missed serving stays missed; I will not double the next serving, exceed the label's three-tablet daily maximum, or extend the intervention to replace missed days.

Full sequence

The full observation period is 54 days. The October 29 bloodwork checkpoint falls inside baseline, before the planned first serving on November 1. These are scheduled dates, not completed observations. The 18 days after stopping are an observation period, not an established pharmacological washout.

Training and surrounding routine

My rolling rotation stays: Legs A, Push A, Pull A, Zone 2 cardio for 60 minutes, Legs B, Push B, Pull B, HIIT for 45 minutes, Off. The baseline includes both A and B sessions. The intervention covers three repetitions of this rotation.

I will avoid deliberate simultaneous changes to the calorie target, protein and carbohydrate intake, cardio volume, caffeine, pre-workout or performance-related compounds. Actual changes to hormones, thyroid treatment, other supplements, sleep treatment, illness or travel stay dated in the log. Necessary medical changes take priority over preserving the comparison.

The separate Safralis experiment is scheduled to begin before this baseline. Its mood and fatigue observations remain separate; improved motivation alone will not be counted as improved lifting performance here.

Three anchor movements

Before baseline begins, I will select and record one comfortable, consistently available movement for each strength category. The proposed choices are below. The final exercise, equipment and setup stay the same throughout the comparison.

The two-set performance capture

1. Use the anchor in the same position in its corresponding workout, with the same warm-up.
2. Select a baseline load that allows approximately 8 to 10 repetitions per set while leaving about two repetitions in reserve.
3. Keep that anchor load fixed and record the first two working sets, with three minutes of rest between them.
4. Use the same range of motion and technique, stopping at approximately two repetitions in reserve on each set.
5. Record each set's repetitions, load, rest and estimated effort, including any deviation.

The session score is set-one reps plus set-two reps. The rest of the workout continues normally. There are no added maximal attempts or extra challenge sets for the experiment. If a load or exercise needs to change, I will record it as a separate comparison segment rather than treat the scores as equivalent.

Capture schedule

Consistent rating anchors

Readiness runs from 0, unable to train, to 10, exceptionally ready. Session effort runs from 0, no effort, to 10, maximal. Pump runs from 0, none, to 10, the strongest I experience. Next-day soreness runs from 0, none, to 10, severely limiting normal movement. I will use these same anchors throughout. Pump is a supporting observation and does not define success.

Bodyweight and tape measurements

Waking bodyweight is recorded under the same usual conditions; the trend matters more than any single day. Waist, relaxed arm and thigh measurements use the same side, anatomical site, tape tension and time of day, before training and without a pump. I will take two readings at each site and average them.

Tape measurements are captured before baseline and at each rotation-end review. No photos are part of this protocol. Weight and circumference changes remain separate from the performance score; they do not automatically represent muscle gained.

Primary comparison

Each anchor has one A-session and one B-session reference from October 23 to 31. Later A sessions are compared with baseline A, and B with baseline B. For each session, I subtract the matching baseline two-set total from the current two-set total. I then summarize the matched rep changes for each exercise within each nine-day rotation, using the median when both sessions are available.

The main assessment uses the final two intervention rotations: November 10 to 18 and November 19 to 27. The first rotation, November 1 to 9, remains in the record as an early-response period. Different exercises keep separate scores; their raw repetitions are not pooled into one total.

What would count as helpful

• At least two of the three anchors improve by a median of at least two total repetitions across the two sets, relative to their matched baseline sessions.
• The same two or more anchors meet that threshold in both final intervention rotations.
• Load, estimated effort, range of motion and technique remain comparable.
• The benefit is worthwhile to me alongside any recovery, blood-pressure or other tolerability tradeoff.

Two extra repetitions is my predefined personal usefulness threshold, not a validated clinical minimum. Both baseline reference sessions will be shown in the final review. A single strong workout or a better pump alone will not meet the primary performance goal.

Measurement coverage

The target is both baseline anchor sessions for every movement, one A and one B, and at least three of the four sessions per anchor in the final two intervention rotations. Those sessions must cover both rotations and both A and B days. The adherence target is at least 24 of 27 recorded daily servings. Missed observations stay missing and are never entered as zero.

Equipment substitutions, travel, illness, unusually poor sleep and major routine changes stay visible beside the scores. Incomplete or materially changed comparisons may leave the result inconclusive. I will not discard difficult days or extend the run until a favorable result appears.

Review dates and follow-up

October 31 closes baseline. November 9 and November 18 are adherence and tolerability reviews, without automatic amount changes. November 27 is the main intervention assessment. Follow-up reviews fall on December 6 and December 15, using the same anchor captures and supporting observations.

Follow-up records persistence or fading of the observed change. Training gains do not have to disappear after stopping for the experiment to be helpful. Continuing Halo, testing another amount, or running a blinded repeat would be a separate decision.

Result labels

Helpful means sustained primary performance improvement that meets the personal threshold with acceptable tolerability. Mixed means a secondary benefit or an important tradeoff without a clear primary success. No signal means a sufficiently complete, comparable run produces no worthwhile change. Inconclusive means missing data or major changes prevent a useful comparison. Intolerable means an adverse effect ends the intervention. No outcome has been assigned yet.

Before the first serving

The October 29 bloodwork review and a check of current resting blood pressure and medication overlap inform the final starting decision. The scheduled November 1 date does not imply that these reviews have already happened. A pharmacist or prescriber review is relevant when other medicines lower blood pressure; I will not change prescribed medicines to make room for Halo.

Resting blood pressure and pulse

During baseline and intervention, I will use the same upper-arm monitor at a consistent time relative to medicines, caffeine and exercise. After five quiet seated minutes, I will take two readings one minute apart and record both with pulse and any symptoms. Where practical, measurement comes before caffeine and exercise; immediate post-workout readings are not treated as resting readings. Symptoms prompt an additional check.

Pause or stop

New persistent dizziness, near-fainting, repeated systolic readings below 90 mmHg, a substantial symptomatic pressure drop, or new palpitations prompt a pause and medical advice. Fainting, chest pain, significant breathlessness or a severe allergic reaction warrants urgent assessment. Any early stop and its reason remain part of the result.

Laboratory follow-up

Whether to repeat a hepatic panel and CK near the end of the intervention will be decided with the clinician from the October 29 review and subsequent symptoms. This is a monitoring option, not a confirmed new order. Exercise and medication timing belong beside any repeated results. Bloodwork will not be used as a direct measure of Halo receptor activity or muscle gained.

Why this product is interesting

Halo Elite is marketed as a plant phytoandrogen based on Eucommia ulmoides bark extract. A 2007 study found androgen- and estrogen-receptor activity in cell experiments and examined enhancement of hormone-related activity in cells and rats. This supplies the mechanism I am interested in testing through an everyday training outcome.

What the performance test answers

The receptor experiments did not test Halo Elite lifting performance in trained people. My experiment asks whether this particular product produces a worthwhile personal performance result at the planned exposure. It does not attempt to measure receptor sensitivity or turn the 100:1 extraction ratio into a testosterone-equivalent amount.

Why blood pressure is included

Greenway and colleagues studied a different, standardized aqueous Eucommia bark extract in people with elevated blood pressure. One study regimen did not change pressure; another reduced it. That finding supports watching my actual readings, without assuming the same magnitude of response from this product or treating those study amounts as interchangeable with Halo Elite.

• Blackstone Labs: Halo Elite: manufacturer product description, Supplement Facts and daily-use directions.
• Ong and Tan, 2007: Eucommia phytoandrogen and hormone-potentiating experiments in cells and rats.
• Greenway et al., 2011: human blood-pressure studies using a different standardized Eucommia bark extract.
• American Heart Association: home blood-pressure monitoring: consistent positioning, rest and repeated readings.